Skip to Main Content

Paper Details

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Clin Cancer Res
58
2019
CDK4/6, Ewing, Ewing Sarcoma, Ewing cell line, Ewing cell lines, Ewing sarcoma, IGF1R, ORF, PI3K, cancer, cancers, cyclin-dependent kinase (CDK)4/6, mTOR, mouse, open reading frame, patients, pediatric malignancies, phospho-IGF1R, tumor, tumor genomes
Author NameAffiliation
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Katherine A JanewayDana-Farber Cancer Institute and Boston Children's Hospital
Jesse S BoehmBroad Institute
Jesse S BoehmBroad Institute
Gabriela AlexeDana-Farber Cancer Institute and Boston Children's Hospital
Gabriela AlexeBoston University
Gabriela AlexeBroad Institute
Gabriela AlexeDana-Farber Cancer Institute and Boston Children's Hospital
Gabriela AlexeBroad Institute
Gabriela AlexeBoston University
Federica PiccioniBroad Institute
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital
Kimberly StegmaierBroad Institute
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital
Kimberly StegmaierBroad Institute
  • 1 - 16

Datasets

Release 1.2